The estimated Net Worth of Paul M Silva is at least $25.9 Milion dollars as of 26 February 2021. Mr. Silva owns over 2,782 units of Vertex Pharmaceuticals stock worth over $4,692,330 and over the last 16 years he sold VRTX stock worth over $18,006,964. In addition, he makes $3,197,860 as Senior Vice President a Controller at Vertex Pharmaceuticals.
Paul has made over 104 trades of the Vertex Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 2,782 units of VRTX stock worth $588,254 on 26 February 2021.
The largest trade he's ever made was exercising 56,295 units of Vertex Pharmaceuticals stock on 9 May 2012 worth over $1,938,237. On average, Paul trades about 2,828 units every 33 days since 2008. As of 26 February 2021 he still owns at least 9,884 units of Vertex Pharmaceuticals stock.
You can see the complete history of Mr. Silva stock trades at the bottom of the page.
Paul M. Silva is Senior Vice President, Controller of the company, and he is no longer as Interim Chief Financial Officer, Effective April 10, 2019. Mr. Silva is our Senior Vice President and Corporate Controller, a position he has held since April 2011. Mr. Silva joined us in August 2007 as Senior Director, Accounting Operations and was our Vice President and Corporate Controller from September 2008 through April 2011. Prior to joining us, he was the Vice President, Internal Reporting at Iron Mountain Incorporated from July 2006 until August 2007 and a consultant to Iron Mountain’s financing department from April 2005 until July 2006. He was the Finance Director of the Bioscience Technologies Division of Thermo Electron Corporation from 2002 to April 2005. Mr. Silva holds a B.S. in accounting from Assumption College.
As the Senior Vice President a Controller of Vertex Pharmaceuticals, the total compensation of Paul Silva at Vertex Pharmaceuticals is $3,197,860. There are 8 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
Paul Silva is 52, he's been the Senior Vice President a Controller of Vertex Pharmaceuticals since 2019. There are 16 older and 8 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
Paul's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden a Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: